MX2012006017A - Compuestos de indol y su uso farmaceutico. - Google Patents

Compuestos de indol y su uso farmaceutico.

Info

Publication number
MX2012006017A
MX2012006017A MX2012006017A MX2012006017A MX2012006017A MX 2012006017 A MX2012006017 A MX 2012006017A MX 2012006017 A MX2012006017 A MX 2012006017A MX 2012006017 A MX2012006017 A MX 2012006017A MX 2012006017 A MX2012006017 A MX 2012006017A
Authority
MX
Mexico
Prior art keywords
group
optionally substituted
substituents selected
alkoxy
compound
Prior art date
Application number
MX2012006017A
Other languages
English (en)
Spanish (es)
Inventor
Teruhiko Inoue
Shinichi Kikuchi
Munenori Maekawa
Tetsudo Kaya
Koji Matsumura
Ritsuki Masuo
Motoya Suzuki
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2012006017A publication Critical patent/MX2012006017A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012006017A 2009-11-25 2010-11-25 Compuestos de indol y su uso farmaceutico. MX2012006017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
PCT/JP2010/070988 WO2011065402A1 (ja) 2009-11-25 2010-11-25 インドール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MX2012006017A true MX2012006017A (es) 2012-06-25

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006017A MX2012006017A (es) 2009-11-25 2010-11-25 Compuestos de indol y su uso farmaceutico.

Country Status (31)

Country Link
US (6) US8299070B2 (enExample)
EP (3) EP2505586B1 (enExample)
JP (6) JP5734628B2 (enExample)
KR (1) KR101766502B1 (enExample)
CN (1) CN102712624B (enExample)
AR (1) AR079164A1 (enExample)
AU (1) AU2010323579C1 (enExample)
BR (1) BR112012012529B1 (enExample)
CA (1) CA2781660C (enExample)
CL (1) CL2012001328A1 (enExample)
CO (1) CO6541645A2 (enExample)
CY (1) CY1117559T1 (enExample)
DK (1) DK2505586T3 (enExample)
ES (1) ES2572935T3 (enExample)
HR (1) HRP20160579T1 (enExample)
HU (1) HUE028016T2 (enExample)
IL (1) IL220009A (enExample)
ME (1) ME02447B (enExample)
MX (1) MX2012006017A (enExample)
MY (1) MY161095A (enExample)
NZ (1) NZ600840A (enExample)
PE (1) PE20121358A1 (enExample)
PH (1) PH12012501021A1 (enExample)
PL (1) PL2505586T3 (enExample)
PT (1) PT2505586E (enExample)
RS (1) RS54910B1 (enExample)
RU (1) RU2556216C2 (enExample)
SI (1) SI2505586T1 (enExample)
SM (1) SMT201600258B (enExample)
TW (1) TWI491591B (enExample)
WO (1) WO2011065402A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
JP2015536950A (ja) * 2012-11-02 2015-12-24 ファーマサイクリックス,インク. Tecファミリーキナーゼ阻害剤アジュバント療法
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
WO2016002918A1 (ja) * 2014-07-04 2016-01-07 日本たばこ産業株式会社 インドール化合物の製造方法
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
EP3804726A4 (en) * 2018-05-25 2022-03-16 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC AGENT WITH AN INDOLE COMPOUND FOR MULTIPLE SCLEROSIS
LT3801546T (lt) * 2018-05-25 2024-08-12 Japan Tobacco Inc. Indolo junginys, skirtas intersticio cistito gydymui
WO2019225741A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
PE20221916A1 (es) 2019-12-20 2022-12-23 Pfizer Compuestos quimicos
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CA3205020A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
CA3205023A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
EP4334302A1 (en) * 2021-05-03 2024-03-13 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
AU2022269594A1 (en) * 2021-05-03 2023-11-16 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
WO2023069514A2 (en) * 2021-10-19 2023-04-27 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
AU2024251390A1 (en) * 2023-04-13 2025-11-27 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
EP1441725A1 (en) * 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
BR0306785A (pt) * 2002-01-07 2004-11-09 Eisai Co Ltd Deazapurinas e seus usos
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
KR20060069490A (ko) 2003-09-08 2006-06-21 아벤티스 파마슈티칼스 인크. 티에노피라졸
US7745641B2 (en) * 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2007076228A2 (en) 2005-12-20 2007-07-05 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
WO2007136790A2 (en) * 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
PE20121358A1 (es) 2012-10-23
JP2020079276A (ja) 2020-05-28
KR20120096540A (ko) 2012-08-30
TW201124378A (en) 2011-07-16
HK1174025A1 (en) 2013-05-31
US20130116240A1 (en) 2013-05-09
CN102712624A (zh) 2012-10-03
SMT201600258B (it) 2016-08-31
JP2017039761A (ja) 2017-02-23
EP2505586B1 (en) 2016-03-02
PL2505586T3 (pl) 2016-12-30
CY1117559T1 (el) 2017-04-26
PH12012501021A1 (en) 2013-01-14
CO6541645A2 (es) 2012-10-16
MY161095A (en) 2017-04-14
JP2021091718A (ja) 2021-06-17
AR079164A1 (es) 2011-12-28
KR101766502B1 (ko) 2017-08-08
SI2505586T1 (sl) 2016-08-31
ES2572935T3 (es) 2016-06-03
RS54910B1 (sr) 2016-10-31
BR112012012529A2 (pt) 2016-05-03
EP2505586A1 (en) 2012-10-03
CA2781660C (en) 2018-06-26
ME02447B (me) 2016-09-20
WO2011065402A1 (ja) 2011-06-03
US8299070B2 (en) 2012-10-30
EP2505586A4 (en) 2013-05-15
AU2010323579A1 (en) 2012-07-19
TWI491591B (zh) 2015-07-11
CA2781660A1 (en) 2011-06-03
BR112012012529B1 (pt) 2021-10-26
JP2011132222A (ja) 2011-07-07
JP2018158935A (ja) 2018-10-11
US20170267662A1 (en) 2017-09-21
US20210284627A1 (en) 2021-09-16
CL2012001328A1 (es) 2012-10-05
EP3059234A1 (en) 2016-08-24
IL220009A (en) 2017-08-31
US20200255408A1 (en) 2020-08-13
PT2505586E (pt) 2016-06-03
JP5734628B2 (ja) 2015-06-17
AU2010323579B2 (en) 2016-05-19
IL220009A0 (en) 2012-07-31
HUE028016T2 (en) 2016-11-28
HRP20160579T1 (hr) 2016-07-29
CN102712624B (zh) 2014-06-04
DK2505586T3 (en) 2016-05-30
RU2556216C2 (ru) 2015-07-10
RU2012126129A (ru) 2013-12-27
AU2010323579C1 (en) 2016-11-03
US20180362506A1 (en) 2018-12-20
NZ600840A (en) 2014-01-31
EP3766877A1 (en) 2021-01-20
US20110306599A1 (en) 2011-12-15
JP2015172051A (ja) 2015-10-01

Similar Documents

Publication Publication Date Title
JP5734628B2 (ja) インドール化合物及びその医薬用途
EP3833671B1 (en) Substituted thienopyrroles as pad4 inhibitors
IL174941A (en) Derivatives of n-[heteroaryl (piperidine-2-yl) methyl] benzamide and pharmaceutical compositions comprising them
US20080293714A1 (en) Tec Kinase Inhibitors
KR20150042801A (ko) 신규한 항균성 화합물
CN117279907A (zh) 吡咯烷酮衍生物及其在医药上的应用
EP2970210B1 (en) Pyrazolylbenzo[d]imidazole derivatives
HK1174025B (en) Indole compound and pharmaceutical use thereof
CN121001991A (zh) 杂环化合物及其使用方法
WO2023236960A1 (zh) 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途

Legal Events

Date Code Title Description
FG Grant or registration